Mouse models of Zika virus transplacental transmission

Antiviral Res. 2023 Feb:210:105500. doi: 10.1016/j.antiviral.2022.105500. Epub 2022 Dec 22.

Abstract

Seven years after the onset of the Zika virus (ZIKV) epidemic in the Americas, longitudinal studies are beginning to demonstrate that children infected in utero and born without severe birth defects exhibit motor skill deficits at up to 3 years of age. Long term health and socioeconomic impacts of fetal ZIKV infection appear imminent. ZIKV continues to circulate in low levels much as the virus did for decades prior to the 2015 epidemic, and the timing of the ZIKV outbreak is unknown. Thus, in the continued absence of ZIKV vaccines or antivirals, small animal models of ZIKV transplacental transmission have never been more necessary to test antiviral strategies for both mother and fetuses, and to elucidate mechanisms of immunity at the maternal-fetal interface. Here we review the state of ZIKV transplacental transmission models, highlight key unanswered questions, and set goals for the next generation of mouse models.

Keywords: Microcephaly; Mouse model; Pregnancy; Transplacental transmission; Vertical transmission; Zika virus.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use
  • Disease Models, Animal
  • Female
  • Fetus
  • Humans
  • Mice
  • Pregnancy
  • Pregnancy Complications, Infectious* / drug therapy
  • Zika Virus Infection* / drug therapy
  • Zika Virus*

Substances

  • Antiviral Agents